Faouzi Djebbari
Oxford, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 27 publications
Belantamab Mafodotin Monotherapy for Multiply-Relapsed Myeloma: A Retrospective Study From the United Kingdom and the Republic of Ireland.
Journal: EJHaem
Published: November 27, 2024
Frailty subgroup analysis of isatuximab with pomalidomide and dexamethasone in a UK-wide real-world cohort of relapsed myeloma patients.
Journal: British journal of haematology
Published: December 11, 2022
Infections in relapsed myeloma patients treated with isatuximab plus pomalidomide and dexamethasone during the COVID-19 pandemic: Initial results of a UK-wide real-world study.
Journal: Hematology (Amsterdam, Netherlands)
Published: June 06, 2022
BCMA-targeted therapies for multiple myeloma: strategies to maximize efficacy and minimize adverse events.
Journal: Expert review of hematology
Published: May 28, 2022
Outcomes of anti-CD38 isatuximab plus pomalidomide and dexamethasone in five relapsed myeloma patients with prior exposure to anti-C38 daratumumab: case series.
Journal: Hematology (Amsterdam, Netherlands)
Published: February 08, 2022
Efficacy and tolerability of VCD chemotherapy in a UK real-world dataset of elderly transplant-ineligible newly diagnosed myeloma patients.
Journal: European journal of haematology
Published: November 30, 2020
Myeloma clinical outcomes following the first wave of COVID-19: results from the Thames Valley Cancer Alliance (UK).
Journal: British journal of haematology
Published: October 25, 2020
Infection-related morbidity in a large study of transplant non-eligible newly diagnosed myeloma patients treated with UK standard of care.
Journal: Haematologica
Published: October 15, 2020
Efficacy and infection morbidity of front-line immuno-chemotherapy in follicular lymphoma.
Journal: European journal of haematology
Published: July 04, 2020
Last Updated: 09/26/2026